Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy
Portfolio Pulse from Benzinga Newsdesk
Bio-Thera Solutions and Biogen have published Phase 3 clinical trial data for TOFIDENCE, a biosimilar to tocilizumab, in the journal Arthritis Research & Therapy. The study shows that TOFIDENCE maintains comparable efficacy and safety to the reference drug Actemra/RoActemra after switching.
September 11, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen, in collaboration with Bio-Thera Solutions, has published positive Phase 3 data for TOFIDENCE, a biosimilar to tocilizumab. The data supports the biosimilarity and safety of TOFIDENCE, potentially enhancing Biogen's biosimilar portfolio.
The publication of positive Phase 3 data for TOFIDENCE, a biosimilar developed by Biogen and Bio-Thera, demonstrates its efficacy and safety, which is crucial for market acceptance and could positively impact Biogen's stock by strengthening its biosimilar portfolio.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80